http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007061285-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a1af05a216369c389c67f763da8b4ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6e4a54a61ccf2f9cb4d46d5160eafe6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86f624006e159cdb081dc21077ed3a56 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2005-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_220949ab58dc48d5aa13a2afaf2fdfd9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58eb16f7fd524b0e53a0b2fedbfd9427 |
| publicationDate | 2007-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2007061285-A1 |
| titleOfInvention | Gonadotropin releasing hormone (gnrh) and luteinizing hormone receptor (lhr) variants: implications for the diagnosis and treatment of breast cancer |
| abstract | The invention relates to the field of medicine and medical diagnostics. More specifically, it relates to methods which predict the chance of breast cancer recurrence and responsiveness to hormone therapy. Provided is a method to predict the recurrence free survival period in a breast cancer patient and the responsiveness of a breast cancer patient to a therapy that interferes with Luteinizing Hormone (LH) signalling, comprising determining in an isolated nucleic acid sample from said patient the presence of a polymorphic variant of the GnRH gene and / or the Luteinizing Hormone receptor (LHR) gene which latter polymorphism results in increased LHR activity, wherein the presence of said polymorphic variant is indicative of a poor disease outcome and an increased chance of being responsive to said therapy. Also provided is a method for the treatment of breast cancer, comprising administering to a subject in need thereof a therapeutically effective dose of a substance capable of suppressing the LH-LHR pathway. |
| priorityDate | 2005-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.